Table 1.
Characteristics of the study population
| Eligible | Participated | HIV-1 positive | Reporting no ART use | Deep-sequenced | Part of phylogenetically inferred transmission chain | Highly supported phylogenetic linkage and direction of transmission | |
|---|---|---|---|---|---|---|---|
| Total | 37,645 | 25,882 | 5142 | 3878 | 2652 | 1334 | 554 |
| Women | 18,946 | 13,791 | 3149 | 2251 | 1447 | 686 | 279 |
| Age | |||||||
| 15–24 | 9203 (24%) | 5839 (23%) | 718 (14%) | 610 (16%) | 403 (15%) | 210 (16%) | 91 (16%) |
| 25–34 | 6158 (16%) | 4905 (19%) | 1463 (28%) | 1104 (28%) | 717 (27%) | 356 (27%) | 141 (25%) |
| 35+ | 3585 (10%) | 3047 (12%) | 968 (19%) | 537 (14%) | 327 (12%) | 120 (9%) | 47 (8%) |
| Men | 18,699 | 12,091 | 1993 | 1627 | 1205 | 648 | 275 |
| Age | |||||||
| 15–24 | 7907 (21%) | 4845 (19%) | 237 (5%) | 215 (6%) | 163 (6%) | 92 (7%) | 33 (6%) |
| 25–34 | 6317 (17%) | 4052 (16%) | 929 (18%) | 817 (21%) | 618 (23%) | 351 (26%) | 145 (26%) |
| 35+ | 4475 (12%) | 3194 (12%) | 827 (16%) | 595 (15%) | 424 (16%) | 205 (15%) | 97 (18%) |
ART, antiretroviral therapy